Back to MRK Overview
NYQ · Valuation Lab
MRK
Merck & Company, Inc.
Last$128.33
Market cap—
EV/EBITDA12.2x
Intrinsic value
$416026205807.12
MoS +100.0% · Undervalued
Assuming 21.4% FCF margin and 4.9% Y1–5 growth.
Upside to price
EV (DCF)459.4B
Terminal share72%
Expected IV$409272890338.66
Probability weights
Projected free cash flows
Stage FCF path with present values · terminal 72% of EV
PV of stage FCFs128.7B
PV of terminal value330.8B
Enterprise value459.4B
Net cash / (debt)-43.4B
Equity value416B
Intrinsic value / share$416026205807.12
| Year | Revenue | FCF | PV | DF |
|---|---|---|---|---|
| Y1 | 69B | 14.8B | 13.9B | 94.3% |
| Y2 | 72.4B | 15.5B | 13.8B | 89.0% |
| Y3 | 75.9B | 16.2B | 13.6B | 84.0% |
| Y4 | 79.6B | 17B | 13.5B | 79.2% |
| Y5 | 83.5B | 17.9B | 13.4B | 74.7% |
| Y6 | 85.6B | 18.3B | 12.9B | 70.5% |
| Y7 | 87.8B | 18.8B | 12.5B | 66.5% |
| Y8 | 90B | 19.3B | 12.1B | 62.7% |
| Y9 | 92.2B | 19.7B | 11.7B | 59.2% |
| Y10 | 94.5B | 20.2B | 11.3B | 55.8% |
| Terminal | — | — | 330.8B | — |
Educational DCF model only — not financial advice. Terminal value and assumptions dominate results; verify filings and run your own diligence.